AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$TRAX

Ware J. Anthony sold $1.8M of TRAX

Ware J. Anthony sold 39,265 shares of First Tracks Biotherapeutics, Inc. (TRAX) at $44.78 ($1.76M total) on 2026-09-02.

Original reporting
SEC EDGAR · Ware J. Anthony
Published Sep 4, 2026, 8:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TRAX
Bearish
medium confidence
Mentioned
$TRAX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TRAXBearishLow
01

Why it matters

The director's sale reduces insider ownership, which may be interpreted as a bearish signal by the market.

02

Market read

Direct insider sale provides fresh material for traders; potential short‑term price impact.

03

What to watch

Sale could be for personal liquidity needs unrelated to confidence in the business.

Relevance 6/10Novelty 5/10Timing: filed Sep 4, 2026

Background

Form 4 filing reports insider transactions; this is the first public disclosure of the sale.

Company-level read

Ticker impact

$TRAXBearishMedium confidence
Context

Director Ware J. Anthony sold 39,265 shares for $1.76M, reducing his stake to 15,660 shares.

Expected impact

Modest downside pressure over the next few days.

Evidence & confidence

Large insider sale by a director, disclosed via Form 4, often leads to sell‑off as market interprets it as a negative signal.

Market effects

Sector

Minimal impact on the broader biotech sector; isolated insider transaction.

Regional

No significant regional effect.

Global

Limited to investors tracking TRAX.

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not necessarily reflect company fundamentals.

Key entities

  • Company
    First Tracks Biotherapeutics, Inc.

    Biotech firm listed under ticker TRAX.

  • Individual
    Ware J. Anthony

    Director of First Tracks Biotherapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TRAX insider trading history →

Related articles

SEP 16
$TRAXHigh

Why is First Tracks Biotherapeutics stock rallying today?

First Tracks Biotherapeutics (TRAX) rose 4.5% after Guggenheim and UBS initiated coverage with Buy ratings and a $100 price target, citing potential in ANB033 for autoimmune diseases. The FDA granted Fast Track designation, and Phase 1b data is expected in Q4 2026. The Nasdaq and S&P 500 also gained 0.8% and 0.4%, respectively.

investing.com1 min
SEP 16
$TRAXMed

First Tracks Biotherapeutics stock rises on Guggenheim buy rating

First Tracks Biotherapeutics (TRAX) shares rose 3.8% after Guggenheim initiated coverage with a Buy rating and $100 price target, citing confidence in its anti-CD122 target and lead asset ANB033 for autoimmune diseases. Guggenheim analyst Yatin Suneja highlighted the company's unique position as the only publicly traded small-to-mid cap firm developing an anti-CD122 monoclonal antibody.

investing.com1 min
AUG 12
$TRAXMed

First Tracks Biotherapeutics, Inc. (TRAX): Results of Operations and Financial Condition

First Tracks Biotherapeutics, Inc. (TRAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update • Completed enrollment for Cohort 1 (gluten challenge) of Phase 1b ANB033 trial in celiac disease (CeD); top-line Cohort 1 data reaffirmed for Q4 2026 • Cohort 2

SEC EDGAR 8-K5 min
JUL 31
$CORTMed

Biotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCR

The following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements. Corcept Therapeutics Incorporated (CORT) Corcept is a biopharmaceutical company engaged in developing medications for metabolic, oncologic, and neurologic diseases. Shares surged over 30% on Thursday to a 52-week high of $122.21.

rttnews.com6 min
JUL 28
$ENTXMed

Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired

Biotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.

rttnews.com6 min
JUL 10
$VRAXMed

Top Biotech Gainers: VRAX Jumps 100% After Fosun Deal, FBRX Soars On Vitiligo Data, TRAX On Watch

Biotech stocks rose on company-specific catalysts. Virax Biolabs (VRAX) jumped over 100% after signing an exclusive multi-country supply agreement with Fosun Diagnostics for ImmuneSelect. Forte Biosciences (FBRX) gained about 78% on positive Phase 1b vitiligo data for FB102. First Tracks (TRAX) rose ~56% without news. TransCode (RNAZ) and Connect Biopharma (CNTB) also climbed; Sanuwave (SNWV) fell guidance and expects Q2 revenue of $8.5m to $9.5m.

rttnews.com6 min